Nervous System Active Pharmaceutical Ingredients Market Share

  • Report ID: 4212
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Nervous System Active Pharmaceutical Ingredients Market Share

North American Market Forecast

Nervous system active pharmaceutical ingredients market in North America is predicted to account for the largest share of 41% by the end of 2036 impelled by the rising spending in healthcare. This, as a result, helps the pharmaceutical companies in the region to allocate more resources for the development of new nervous system active pharmaceutical ingredients to combat several neurological and cardiovascular diseases.

Besides this, rising investment in healthcare may also enable the development of novel drug delivery systems in the region for neurological diseases which necessitates the usage of nervous system APIs. According to data, the US spends the most on healthcare, and in 2021, health expenditures in the United States rose by more than 2%.

APAC Market Statistics

The Asia Pacific nervous system active pharmaceutical ingredients market is estimated to be the second largest share of 30%, during the forecast timeframe led by low labor costs. For instance, owing to the availability of cheap labor in countries such as India and Indonesia results in increasing production capacity for nervous system active pharmaceutical ingredients which can lead to an increased demand for these APIs in both local and international markets.

Research Nester
Nervous System Active Pharmaceutical Marke
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Rajrani Baghel


  • Report ID: 4212
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nervous system active pharmaceutical ingredients is assessed at USD 218.26 Billion.

The nervous system active pharmaceutical ingredients market size was over USD 209.4 Billion in 2023 and is expected to reach USD 380.44 Billion by the end of 2036, witnessing around 4.7% CAGR during the forecast period i.e., between 2024-2036. The growing presence of chronic diseases across the globe and the growing geriatric population are the major factors driving the growth of the market.

Asia Pacific industry is estimated to be the second largest share of 30% by 2036, led by low labor costs in the region.

Pfizer, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Shenzhen Hepalink Pharmaceutical Co. Ltd., GSK plc, F. Hoffmann-La Roche Ltd, Cipla Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample